A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C
- 1 October 2002
- journal article
- clinical trial
- Published by Springer Nature in Molecular Psychiatry
- Vol. 7 (9) , 942-947
- https://doi.org/10.1038/sj.mp.4001119
Abstract
Molecular Psychiatry publishes work aimed at elucidating biological mechanisms underlying psychiatric disorders and their treatmentKeywords
This publication has 25 references indexed in Scilit:
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis CHepatology, 2001
- Hepatitis C, interferon alfa, and depressionHepatology, 2000
- Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A ReviewAmerican Journal of Psychiatry, 2000
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Hepatitis C and depressionDepression and Anxiety, 1998
- Epidemiology of hepatitis CHepatology, 1997
- PSYCHIATRIC SIDE EFFECTS OF INTERFERONThe Journal of Toxicological Sciences, 1996
- Neurological and Psychiatric Adverse Effects of Immunological TherapyCNS Drugs, 1995
- Suicide associated with alfa-interferon therapy for chronic viral hepatitisJournal of Hepatology, 1994